Image

Asia-Pacific Patient Derived Xenograft (PDX) Models Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Nov 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • Nov 2022
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Asia-Pacific Patient Derived Xenograft (PDX) Models Market, By Type (Mice Models, Rat Models), Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Lung Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Others), Application (Preclinical Drug Development and Oncology Research, Precision Medicine, Co-Clinical Trials, Basic Cancer Research, Biomarker Analysis), Technique (Heterotopic Implantation, Orthotropic Implantation), End User (Contract Research Organization, Academic and Research Institutions, Pharmaceutical and Biotechnology Companies and Others) – Industry Trends and Forecast to 2030.

Asia-Pacific Patient Derived Xenograft (PDX) Models Market

Asia-Pacific Patient Derived Xenograft (PDX) Models Market Analysis and Size

According to the American Cancer Society, there were 1,735,350 new cases of cancer diagnosed in the United States in 2018. In addition, the National Institute of Cancer is expanding its repository of cancer research models in 2018 to include more research models. In Asia-Pacific and the United States, large-scale PDX libraries are now being built. The National Cancer Institute of the United States announced plans to transition its anti-cancer drug screening system from the "NCI-60 Human Tumor Cell Line" to a new system. Compared to cell line-derived xenograft models, PDX models are expected to have superior predictability of treatment efficacy while preserving tumour heterogeneity.

Data Bridge Market Research analyses that the patient derived xenograft (PDX) models market which was USD 36424.39 thousand in 2022, is expected to reach USD 140671.43 thousand by 2030, at a CAGR of 18.4% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Asia-Pacific Patient Derived Xenograft (PDX) Models Market Scope and Segmentation      

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Thousand, Volumes in Units, Pricing in USD

Segments Covered

Type (Mice Models, Rat Models), Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Lung Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Others), Application (Preclinical Drug Development and Oncology Research, Precision Medicine, Co-Clinical Trials, Basic Cancer Research, Biomarker Analysis), Technique (Heterotopic Implantation, Orthotropic Implantation), End User (Contract Research Organization, Academic and Research Institutions, Pharmaceutical and Biotechnology Companies and Others)

Countries Covered

China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)

Market Players Covered

Crown Bioscience Inc. (U.S.), THE JACKSON LABORATORY (U.S.), Champions Oncology, Inc. (U.S.), Charles River Laboratories (U.S.), Wuxi AppTec (China), Oncodesign (Canada), Aragen Bioscience (India), Biocytogen (U.S.), Bioduro (U.S.), Creative Animodel (U.S.), Covance Inc. (U.S.), EPO Berlin-Buch GmbH (Germany), EUROPDX. (Belgium), Explora BioLabs (U.S.), Hera BioLabs (U.S.), Horizon discovery Ltd. (U.K.), Pharmatest Services (Finland), Urospehere SAS (Cyprus), Xentech (France), Xenopat (France)

Market Opportunities

  • Growing adoption of humanized PDX models
  • Increased R&D efforts in the pharmaceutical industry
  • Ongoing governmental and private sector support for cancer research

Market Definition

PDX models are considered an effective tool in biomedical research and preclinical trials because both species have similarities and these models are capable of carrying the tumour's characteristics and studying the tumour and its heterogeneity. They aid in assessing tumour growth rate, life cycle, and growth rate under various conditions. They also aid in distinguishing between adult and paediatric cancer. The use of PDX models in basic cancer research and rug development enables the adoption of new therapies, patient-specific therapies, and personalized medicine.

Asia-Pacific Patient Derived Xenograft (PDX) Models Market Dynamics

Drivers

  • Rising demand for PDX models for pharmacology and biomarker studies

Tumor xenograft and syngeneic models were traditionally used for oncology pharmacology, biomarker, and pharmacokinetics/pharmacodynamics research. The value of PDX models in normal research operations has increased as the availability and cost of PDX models supplied by both academic institutions and contract research businesses have increased. A cursory review of cancer discovery programmes published in the last three years reveals the use of PDX models at various stages of preclinical discovery and translational research. However, the PDX Model industry is increasingly incorporating PDX model readout as a critical component of the required data package for both internal usage and regulatory submission. The use of PDX models in drug development can be trace the use of PDX models in drug development back several decades.

  • Growing prevalence of chronic diseases rising the demand for personalized medicines

The development of medicines for chronic diseases such as cancer has received a lot of attention. Cancer is now a major burden on healthcare systems worldwide. According to Worldwide cancer data released in 2020, approximately 18 million cancer cases and 10 million cancer deaths were recorded in 2020. In vitro and in vivo techniques are being developed to address the rising incidence of cancer and provide effective therapies to patients. Cancer is one of the leading causes of death worldwide. The disease has spread rapidly and is expected to spread significantly during the forecast period.

Each year, approximately 400 000 children are diagnosed with cancer. The most common cancers differ by country. As a result of the rising global prevalence of cancer, the market is being driven by an increase in the rate of diagnosis and demand for personalized medication.

Opportunities

  • Growing adoption of humanized PDX models

Despite the fact that xenografts develop well in immunodeficient models, these models are primarily used to create PDX models. These models are insufficient for investigating stroma-tumour interactions, primarily responsible for tumour development and progression in patients. Humanized PDX models help with these challenges and are gaining popularity in the industry. To generate humanised xenograft models, immunodeficient mice (such as NOD SCID mice) are being reconstructed with bone marrow or peripheral blood cells and patient tumour implants. These models are ideal for studying the role of xenogeneic immune cells in overall anti-tumor immunity. They also help with the development of immunotherapy medications that target the immune system's effector arm.

Restraints/Challenges

  • Unaffordable personalized PDX models

To develop individualized PDX models, a specimen of the patient's tumour is implanted and grown in a variety of immunocompromised models. It is then extracted, fragmented, and re-implanted in a larger group of models that have been treated with various medications and pharmacological combinations. Given the costs of developing and maintaining these models and the use of expensive medications in these models, PDX trials can cost thousands of dollars, even for a single patient. Using PDX models in government-funded fundamental research, on the other hand, could be prohibitively expensive. These are the primary factors limiting the adoption of PDX models.

This patient derived xenograft (PDX) models market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the patient derived xenograft (PDX) models market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Asia-Pacific Patient Derived Xenograft (PDX) Models Market

Covid-19 had a negative impact on the Asia-Pacific patient-derived xenograft (PDX) models market due to the decline in productivity in life science organizations during the pandemic. Reduced pharma R&D deals in therapeutic areas, disruption of clinical trials, and country-specific lockdowns all affected the market. Oncology, ID/anti-infectives, cardiovascular disease, and respiratory disease trials were the most impacted. The market will resume growth as the impact of COVID-19 is expected to weaken in the post-pandemic scenario.

Recent developments

  • In December 2020, Collagen Matrix, Inc., a global leader in collagen-based, regenerative, xenograft-derived medical devices, and Linden Capital Partners ("Linden") announced the acquisition of Sunstar's Degradable Solutions division. It included the GUIDOR branded line of resorbable synthetic medical implants. The investment aims to broaden the range of technologies available to customers.
  • In April 2020, Crown Bioscience Inc. acquired unique models from Leading Academic Medical Centres, and the company signed agreements with Dana-Farber Cancer Institute and the University of Washington. This aids the company's product expansion and assists the oncology drug development community.

Asia-Pacific Patient Derived Xenograft (PDX) Models Market Scope

The patient derived xenograft (PDX) models market is segmented on the basis of type, tumour type, application, technique and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Mice Models
  • Rat Models

Tumor Type

  • Gastrointestinal Tumor Models
  • Lung Tumor Models
  • Haematological Tumor Models
  • Gynecological Tumor Models
  • Respiratory Tumor Models
  • Urological Tumor Models
  • Others

Application

  • Preclinical Drug Development
  • Precision Medicine
  • Co-Clinical Trials
  • Basic Cancer Research
  • Biomarker Analysis
  • Oncology Research

Technique

  • Heterotopic Implantation
  • Orthotropic Implantation

End User

  • Academic and Research Organizations
  • Contract Research Organizations
  • Pharmaceutical and Biotechnological Companies
  • Others

Patient Derived Xenograft (PDX) Models Market Regional Analysis/Insights

The patient derived xenograft (PDX) models market is analyzed and market size insights and trends are provided by country, type, tumour type, application, technique and end user as referenced above.

The countries covered in the patient derived xenograft (PDX) models market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).

Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2023 to 2030 due to surge in the demand of personalized medicines for specific cancer patients and tumours patients and due to the wide adoption of PDX models in preclinical research. China is leading the growth of the Asia-Pacific market due to strategic initiatives by private and government sector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The patient derived xenograft (PDX) models market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for patient derived xenograft (PDX) models market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the patient derived xenograft (PDX) models market. The data is available for historic period 2010-2020.

Competitive Landscape and Patient Derived Xenograft (PDX) Models Market Share Analysis

The patient derived xenograft (PDX) models market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to patient derived xenograft (PDX) models market.

Some of the major players operating in the patient derived xenograft (PDX) models market are:

  • Crown Bioscience Inc. (U.S.)
  • THE JACKSON LABORATORY (U.S.)
  • Champions Oncology, Inc. (U.S.)
  • Charles River Laboratories (U.S.)
  • Wuxi AppTec (China)
  • Oncodesign (Canada)
  • Aragen Bioscience (India)
  • Biocytogen (U.S.)
  • Bioduro (U.S.)
  • Creative Animodel (U.S.)
  • Covance Inc. (U.S.)
  • EPO Berlin-Buch GmbH (Germany)
  • EUROPDX. (Belgium)
  • Explora BioLabs (U.S.)
  • Hera BioLabs (U.S.)
  • Horizon discovery Ltd. (U.K.)
  • Pharmatest Services (Finland)
  • Urospehere SAS (Cyprus)
  • Xentech (France)
  • Xenopat (France)

Research Methodology: Asia-Pacific Patient Derived Xenograft (PDX) Models Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-
Why Choose Us


Frequently Asked Questions

The Asia-Pacific Patient Derived Xenograft (PDX) Models Market is projected to grow at a CAGR of 18.4% during the forecast period by 2030.
The future market value of the Asia-Pacific Patient Derived Xenograft (PDX) Models Market is expected to reach USD 140671.43 thousand by 2030.
The major players in the Asia-Pacific Patient Derived Xenograft (PDX) Models Market are Crown Bioscience Inc. (U.S.), THE JACKSON LABORATORY (U.S.), Champions Oncology, Inc. (U.S.), Charles River Laboratories (U.S.), Wuxi AppTec (China), Oncodesign (Canada), Aragen Bioscience (India), etc.
The countries covered in the Asia-Pacific Patient Derived Xenograft (PDX) Models Market are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).